Mainstay Medical announces € 30 million financing new capital to complete US Pivotal ReActiv8-B clinical study and advance european commercialization
Dublin, Ireland: 15 February 2018 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, announces today that it has raised gross proceeds of €30.1 million through the issue of 2,151,332 new ordinary shares (New Shares) to new and existing shareholders.
More info on Mainstay Medical's website.
Next > Confo Therapeutics is awarded a € 1 million grant to increase its screening capabilities
Previous > Mainstay Medical publishes 2017 full year results